Program
SIM0811
A development code. Also written as “SIM0811 Dose Level A (Phase II)”, “SIM0811 Dose Level B (Phase II)” and “SIM0811 Dose Level C (Phase II)”.
Its studies are mostly in Ischemic Stroke, led by Simcere Pharmaceutical Group.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Simcere Pharmaceutical Group | 21 open or running | phase 3since Oct 23, 2026 | Dec 26, 2025 | Jun 30, 2029phase 3 · NCT07903701 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 26, 2025First study: phase 1 study in Health, SubjectiveFirst studyNCT07345364 · 64 enrolled · China
- Oct 23, 2026Phase 3 study in Acute Ischemic Stroke AISPhase 3 reachedNCT07903701 · 1,092 planned
Ahead
- Jun 30, 2029Primary completion: phase 3 study in Acute Ischemic Stroke AISNCT07903701
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07903701Acute Ischemic Stroke AIS | 3 | Not yet recruiting | Jun 30, 2029 | 1,092 |
| NCT07345364Health, Subjective · China | 1 | Completed | Jun 18, 2026 | 64 |
How it is read
Names in the registry
- “SIM0811 Dose Level A (Phase II)”, 1 entry
- “SIM0811 Dose Level B (Phase II)”, 1 entry
- “SIM0811 Dose Level C (Phase II)”, 1 entry
- “SIM0811(Phase III)”, 1 entry
- “SIM0811”, 1 entry
Codes read as this program: SIM0811.
Conditions, from the studies’ own filings
- Ischemic Stroke, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.